Q4 EPS Estimate for Esperion Therapeutics Raised by Analyst

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at Zacks Research upped their Q4 2026 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued to investors on Tuesday, March 31st. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings of $0.04 per share for the quarter, up from their previous forecast of $0.03. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q1 2027 earnings at $0.06 EPS, Q2 2027 earnings at $0.10 EPS and FY2028 earnings at $0.39 EPS.

ESPR has been the subject of a number of other research reports. Citizens Jmp raised their price target on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “market outperform” rating in a report on Friday, March 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a research report on Tuesday, March 10th. Needham & Company LLC raised their target price on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Finally, Wall Street Zen upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.60.

Esperion Therapeutics Price Performance

NASDAQ:ESPR opened at $2.74 on Wednesday. The firm has a market capitalization of $702.38 million, a price-to-earnings ratio of -16.09, a PEG ratio of 1.89 and a beta of 1.11. The company’s 50-day moving average is $3.09 and its two-hundred day moving average is $3.17. Esperion Therapeutics has a 1-year low of $0.69 and a 1-year high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Tuesday, March 10th. The biopharmaceutical company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The company had revenue of $168.45 million for the quarter, compared to analysts’ expectations of $165.12 million.

Institutional Investors Weigh In On Esperion Therapeutics

Several large investors have recently bought and sold shares of ESPR. Orbimed Advisors LLC purchased a new stake in shares of Esperion Therapeutics during the fourth quarter worth approximately $22,072,000. Eversept Partners LP purchased a new position in Esperion Therapeutics in the fourth quarter worth approximately $14,249,000. Two Seas Capital LP lifted its stake in Esperion Therapeutics by 43.6% in the second quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock worth $9,800,000 after acquiring an additional 3,024,104 shares during the last quarter. AIGH Capital Management LLC acquired a new position in Esperion Therapeutics during the 3rd quarter worth approximately $7,950,000. Finally, Millennium Management LLC grew its holdings in Esperion Therapeutics by 303.4% during the 4th quarter. Millennium Management LLC now owns 3,932,274 shares of the biopharmaceutical company’s stock worth $14,549,000 after acquiring an additional 2,957,418 shares in the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.